Scientists May Have Found the Blueprint of the Human Body in the Ocean
One major division of the kingdom Animalia is Cnidarians (animals built around a central point) and bilaterians (animals with bilateral symmetry), which includes us humans.
A new study found that the sea anemone, a member of the Cnidarian phylum, uses bilaterian-like techniques to form its body.
This suggests that these techniques likely evolved before these two phyla separated evolutionarily some 600 to 700 million years ago, though it can't be ruled out that these techniques evolved independently.
Make a list of complex animals as distantly related to humans as possible, and sea anemones would likely be near the top of the list. Of course, one lives in the water and the other doesn't, but the differences are more biologically fundamental than that—sea anemones don't even have brains.
So it's surprising that this species in the phylum Cnidarians (along with jellyfish, corals, and other sea creatures) contains an ancient blueprint for bilaterians, of which Homo sapiens are a card-carrying member. A new study by a team of scientists at the University of Vienne discovered that sea anemones, whose Cnidarian status means they grow radially around a central point (after all, what is the 'face' of a jellyfish), use a technique commonly associated with bilaterians, known as bone morphogenetic protein (BMP) shuttling, to build their bodies. This complicates the picture of exactly when this technique evolved or if it possibly evolved independently of bilaterians. The results of the study were published last month in the journal Science Advances.'Not all Bilateria use Chordin-mediated BMP shuttling, for example, frogs do, but fish don't, however, shuttling seems to pop up over and over again in very distantly related animals making it a good candidate for an ancestral patterning mechanism,' University of Vienna's David Mörsdorf, a lead author of the study, said in a press statement. 'The fact that not only bilaterians but also sea anemones use shuttling to shape their body axes, tells us that this mechanism is incredibly ancient.'
To put it simply, BMPs are a kind of molecular messenger that signals to embryonic cells where they are in the body and what kind of tissue they should form. Local inhibition from an inhibitor named Chordin (which can also act as a shuttle) along with BMP shuttling creates gradients of BMP in the body. When these levels are their lowest, for example, the body knows to form the central nervous system. Moderate levels signal kidney development, and maximum levels signal the formation of the skin of the belly. This is how bilaterians form the body's layout from back to body.
Mörsdorf and his colleagues found that Chordin also acts as a BMP shuttle—just as displayed in bilaterians like flies and frogs. Thi signals that this particular evolutionary trait likely developed before Cnidarians and bilaterians diverged. Seeing as these two phylums of the animal kingdom have vastly different biological structures, that divergence occurred long ago, likely 600 to 700 million years ago.
'We might never be able to exclude the possibility that bilaterians and bilaterally symmetric cnidarians evolved their bilateral body plans independently,' University of Vienna's Grigory Genikhovich, a senior author of the study, said in a press statement. 'However, if the last common ancestor of Cnidaria and Bilateria was a bilaterally symmetric animal, chances are that it used Chordin to shuttle BMPs to make its back-to-belly axis.'
You Might Also Like
Can Apple Cider Vinegar Lead to Weight Loss?
Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
This Viral, At-Home Fitness Test Claims to Predict Longevity—but There's a Catch
Dimensions/Getty Images New blood tests, scans, and fitness trackers that purport to predict longevity are rolling out all the time, but if you've scrolled TikTok recently, you might be surprised to see a much lower-tech way getting some buzz: how well you fare in simply trying to haul your butt off the floor. It's all based on the takeaway from a study published in the European Journal of Preventive Cardiology that's been making the rounds. In it, researchers had more than 4,000 people do something they dubbed the 'sitting-rising' test and then followed up with them for over a decade. They found a link between how easily people were able to get up off the floor and how long they lived. The task sounds simple, but, as I learned firsthand, it's really not. To get a perfect score on the test, you need to be able to get from a position on the floor—usually cross-legged—to standing without using a hand, elbow, or knee to help. As a former competitive athlete who can't say no to a challenge, I needed to try this (and gain a perfect score) once it came across my FYP. To my surprise, it was hard. While I was able to get it done, I had to give myself a mental pep talk before each attempt. Pulling this test off is trickier than it sounds—it requires a combination of strength, balance, and flexibility, and I struggle to even touch my toes. So that made me wonder: How legit is it, really, in predicting your, um, ultimate demise? Does bombing the test mean you're going to keel over any second? I checked in with longevity experts and fitness pros to find out. One of the benefits of the sitting-rising test is you can do it right at home: Sit on the floor with your legs crossed in front of you and then try to get back up unassisted. The goal is to do this with as little support as possible, test inventor and lead study author Claudio Gil S Araújo, MD, a sports and exercise physician from the Exercise Medicine Clinic Clinimex in Rio de Janeiro, tells SELF. (Check out this handy YouTube video Dr. Araújo and his fellow researchers created to break it down in more detail.) The test is scored from zero to 10, with points assigned for sitting and rising added together. You'll be docked a point for each knee, hand, or forearm you use during the test, along with half-points if you're unsteady (say, you stumble when you get up). 'If you're an eight, why did you lose a point? It may mean that you used one hand to sit and one hand to rise,' Dr. Araújo says. In the study, the researchers discovered a link between how well people scored on the test and their risk of dying during a follow-up of about 12 years. In all, about 16% of the participants died during that period—but only 4% of folks who aced the test with a perfect 10 did so. (On the other end of the spectrum, people who got a four or less had a death rate of 42% during that time.) Okay, but…why? The test measures a few different things that are linked to better health and longevity, study co-author Jonathan Myers, PhD, a clinical professor at Stanford University and a health research scientist at the Palo Alto VA Health Care System, tells SELF. 'When we think of 'fitness,' people usually think of 'aerobic' or cardiorespiratory fitness,' he says. 'Over the last three decades or so, cardiorespiratory fitness has become recognized as a powerful predictor of health outcomes—in many studies, it is even more powerful than the traditional risk factors such as smoking, hypertension, or [high cholesterol].' Cardiorespiratory fitness is important, sure—it's considered a strong indicator of overall health, along with being linked to a lower risk of developing certain diseases. But fitness is more broad than that, and includes things like strength and balance, Dr. Myers says. Strength has been shown to help with daily living (think: being able to carry your own groceries), while balance helps to protect against falls, Dr. Araújo explains. These skills are important for longevity, and they're something that Hannah Koch, PT, DPT, physical therapist at Michigan State University Health Care, tells SELF she checks with older patients, along with their range of motion. The sitting-rising test looks at strength, power, and balance, all in one move. So basically, you're getting more bang for your buck, looking at all of these factors at once. Added bonus: It can also give some insight on your cardiovascular health, Jennifer Wong, MD, cardiologist and medical director of Non-Invasive Cardiology at MemorialCare Heart and Vascular Institute at Orange Coast Medical Center in Fountain Valley, California, tells SELF. 'One could not do this after certain types of strokes or if too weak from poor overall health,' she adds. While the test is predictive, it's by no means perfect: There are some flaws with it. 'The test does not identify the underlying cause of poor performance,' Anna A. Manns, PT, DPT, lead physical therapist at University Hospital in New Jersey, tells SELF. Meaning, it can't tell if you struggle with getting up due to joint pain, an injury, or the fact that you went hard at the gym yesterday—and those factors don't necessarily have an impact on your longevity. It's also possible to game the test, say, by 'compensating with upper-body movement or momentum by using arm swings or trunk movement to 'cheat' the test,' Dr. Mann says, which would 'mask true lower-limb weakness.' The test also only looks at lower-body function and core strength, so it doesn't gauge your overall fitness, upper-body strength or endurance, 'all of which are important for full functional capacity,' she adds. While the sitting-rising test has a link with longevity, there are plenty of others that healthcare providers use regularly. Simple hand-grip tests, which measure grip strength, are a 'powerful predictor of mortality,' Dr. Myers says. Case in point: A 2015 study published in The Lancet found that grip strength was better at predicting someone's odds of dying from heart disease or other causes during the follow-up than systolic blood pressure, which is usually used to gauge cardiovascular health. Balance tests, like the ability to stand on one leg for 10 seconds or longer, can also be helpful, Dr. Myers says. Koch also flags the Five Times Sit-to-Stand Test (5TSTS) as a useful way to check a person's lower-body strength and balance. It's similar to the sitting-rising test, but has people get up from a chair versus the floor five different times. The Timed Up and Go (TUG) test, which has people get up from a chair, walk a short distance, turn around, walk back, and sit back down while being timed, is useful too, says Manns. 'Together, these tests provide a patient picture of overall physical function and longevity,' Manns says. That said, they're still only a part of the overall picture of your health. There's no reason to get down on yourself if you don't do well on the sitting-rising test—not getting a perfect 10 on the sitting-rising test certainly doesn't mean you're doomed. But it could clue you in on areas of fitness to work on, Dr. Araújo says. That may mean working on balance training, flexibility, or building power. 'This helps a lot to get people motivated,' Dr. Araújo says. Dr. Myers agrees that your mobility, strength, flexibility, and balance can usually be improved with practice and training. 'Individuals who don't perform well on these tests can improve their performance by strengthening lower body muscles, and specific exercises can be targeted to improve flexibility, balance, gait, and mobility,' he says. Albert Matheny, CSCS, cofounder of SoHo Strength Lab, suggests focusing on things like squats, single-leg exercises like lunges, and even balancing on one leg to hit these areas. It's also important to remember that these tests are only part of the puzzle: There are a bunch of health-promoting behaviors out there that have nothing to do with how well you can get up off the floor—or even how well you move in general. While physical activity is important, other things, like eating a high-quality diet, minimizing stress, getting plenty of sleep, and adopting other healthy lifestyle habits like avoiding smoking and minimizing alcohol, also come in handy. Together, these can help you be your healthiest self. 'The sitting-rising test is a good screening tool,' Dr. Araújo says. 'There's a lot we can do to move forward after that.' Related: 6 Daily Habits Doctors Say Will Help You Live Longer 5 Ways Strong Friendships Can Benefit Your Health as You Get Older Exactly How Your Skin Changes in Your 40s, 50s, and 60s Get more of SELF's great fitness coverage delivered right to your inbox—for free. Originally Appeared on Self
Yahoo
an hour ago
- Yahoo
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
Health authorities in major European countries have accepted the reclassification of JNJ-1900 (NBTXR3) from a medical device to a medicinal product, aligning with regulatory status in the US and other major markets Medicinal product classification supports unified global regulatory classification, facilitating future global strategies and filings New composition of matter patent for JNJ-1900 (NBTXR3) filed by Nanobitotix PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ''Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica NV, a Johnson & Johnson company. Health authorities in major European countries have agreed to formally reclassify JNJ-1900 (NBTXR3) from a medical device to a drug, completing a process initiated by Johnson & Johnson to harmonize the product candidate's regulatory status with classifications already in place in the United States and other major markets. The reclassification follows updated insights into the product candidate's mechanism of action. In parallel, Nanobiotix has filed a new composition of matter patent for JNJ-1900 (NBTXR3) that aims to reinforce the intellectual property foundation supporting the product candidate. 'These updates reflect our continued commitment to the JNJ-1900 (NBTXR3) program,' said Laurent Levy, co-founder and chairman of the executive board at Nanobiotix. 'We are pleased with the progress achieved with health authorities and proud to continue advancing this potential first-in-class product candidate toward patients in need.' JNJ-1900 (NBTXR3) is currently the subject of a comprehensive global clinical development program across multiple tumor types and therapeutic combinations, including a pivotal Phase 3 trial in head and neck cancer. About JNJ-1900 (NBTXR3) JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. Its proof-of-concept was achieved in soft tissue sarcomas through a successful randomized Phase 2/3 study in 2018. The product candidate's mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that JNJ-1900 (NBTXR3) could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors. Radiotherapy-activated JNJ-1900 (NBTXR3) is being evaluated across multiple solid tumor indications as a single agent or combination therapy. The program is led by NANORAY-312—a global, randomized Phase 3 study in locally advanced head and neck squamous cell cancers. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of JNJ-1900 (NBTXR3) activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy—the same population being evaluated in the Phase 3 study. Given the Company's focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations. In 2023, Nanobiotix announced a license agreement for the global co-development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company. About NANOBIOTIX Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations. Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. For more information about Nanobiotix, visit us at or follow us on LinkedIn and Twitter Disclaimer This press release contains 'forward-looking' statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company's anticipates its financial resources will be adequate to support operations. Words such as 'expects', 'intends', 'can', 'could', 'may', 'might', 'plan', 'potential', 'should' and 'will' or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company' management's current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix's business and financial performance, which include the risk that assumptions underlying the Company's cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix's Annual Report on Form 20-F filed with the SEC on April 02, 2025 under 'Item 3.D. Risk Factors', in Nanobiotix's 2024 universal registration document filed with the AMF on April 02, 2025,, and subsequent filings Nanobiotix makes with the SEC from time to time which are available on the SEC's website at The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly. Contacts Nanobiotix Communications DepartmentBrandon OwensVP, Communications+1 (617) 852-4835contact@ Investor Relations DepartmentJoanne ChoiVP, Investor Relations (US)+1 (713) 609-3150investors@ BhajunDirector, Investor Relations (EU)+33 (0)1 79 97 29 99investors@ Media Relations France – HARDYCaroline Hardy+33 06 70 33 49 Global – uncapped CommunicationsBecky Lauer +1 (646) 286-0057 nanobiotixteam@ Attachment 2025-07-07 -- NTBX -- Composition of Matter Patent for NBTXR3 -- FINALSign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
Your dog is ignoring you and staring at nothing? It could be dementia
Sometimes Jackie just stands there and stares. "He looks off into nothingness," is how his owner describes the state of her 15-year-old Jack Russell Terrier. The small white dog is physically very fit, but he suffers from dementia. Sometimes he seems not to recognise family members and growls at them. Or he goes from the house into the garden, immediately returns and shortly afterwards stands at the door again, wanting to go out. "And this happens 15 times in a row. As if he has forgotten that he was just outside." Pets are living longer in many parts of the world, and dementia is no longer uncommon among them. According to one study, 68% of dogs at Jackie's age are affected. "It can start from the age of eight," said Julia Hauer, senior neurologist at a veterinary clinic in western Germany. The disease develops gradually over months. Initially, the symptoms are so non-specific that owners often do not realise something is wrong with their pet. Moreover, these symptoms could also be signs of a normal ageing process. Affected animals may wander around a lot, especially at night. They no longer interact with their humans as they used to; some become incontinent, and they fail to understand common commands like "sit" or "stay." They may no longer be able to find food on the floor, get scared in familiar situations, bark or whine without any apparent reason, or repeatedly stare at nothing. "When animals suspected of having dementia come to the consultation, I often ask their owners if they try to enter through the wrong side of a familiar door," the veterinarian explained as another possible symptom. Additionally, there are questionnaires for owners to fill out, covering topics such as anxiety, sleep patterns and house training. Diagnosing dementia is not easy, as there are numerous possible causes for behavioural changes. "Ultimately, it is a diagnosis of exclusion," says veterinarian Klaus Kutschmann. Initially, the vet will discuss the symptoms and their progression with the owner, followed by physical examinations — general, neurological and orthopaedic. The eyes and teeth are also checked. "The decisive examinations are MRI and cerebrospinal fluid analysis," Kutschmann says. However, these require the animal to be put under general anaesthesia, which is not always advisable given their age. What happens if the diagnosis is dementia? "There is no pill you can give to make everything better," says Hauer. However, there are many ways to make life easier for the dog. The first question is how the dog is doing apart from the dementia. Does it perhaps have toothache or chronic pain from arthritis? Pain exacerbates dementia symptoms. Addressing this improves its quality of life. Or could the dog maybe have impaired vision or hearing? In such cases, the owner can adapt their communication, for example, by speaking louder or using visual commands. To help the dog sleep through the night again, melatonin can be given, but only in consultation with a vet. But melatonin approved for humans is not suitable for dogs, vets say. Treats containing this sleep hormone are also not recommended, as the dosage is too low. Studies have also shown that supplements like Aktivait or Senilife improve brain activity, Hauer says. The same goes for MCT oil. Additionally, there are medications like selegiline, although not all animals respond to them. A stable daily routine is essential for four-legged dementia patients. Everything should happen at the same time each day: waking up, walks, feeding and sleeping. However, some variety should also be included, says Hauer, suggesting taking walks in different places or hiding treats. New toys, like a sniffing mat, can also provide mental stimulation. Kutschmann also advised "lots of attention and activity." "Interestingly, there are many parallels between dogs with dementia and human Alzheimer's patients," says Hauer. As with humans, dementia progresses very differently in animals. It's entirely possible for a dog to live well with the condition until its death. In some cases, however, the disease progresses rapidly, causing the dog to suffer from confusion, sleep deprivation or constant wandering. In these cases, some vets may give you the choice to euthanize the animal to end its suffering.
